Brokers Issue Forecasts for ImmunityBio FY2027 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) – HC Wainwright raised their FY2027 earnings estimates for shares of ImmunityBio in a research report issued to clients and investors on Monday, January 26th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn $0.05 per share for the year, up from their prior estimate of ($0.01). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for ImmunityBio’s current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio’s FY2028 earnings at $0.33 EPS and FY2029 earnings at $0.55 EPS.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. The company had revenue of $32.06 million during the quarter, compared to analysts’ expectations of $31.88 million.

Several other analysts also recently weighed in on the stock. Jefferies Financial Group lifted their price target on shares of ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital restated a “buy” rating and set a $24.00 price target on shares of ImmunityBio in a research report on Tuesday, January 20th. BTIG Research raised their target price on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Piper Sandler upped their target price on ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $11.80.

ImmunityBio Stock Up 5.8%

Shares of NASDAQ:IBRX opened at $6.25 on Thursday. The firm’s 50 day moving average price is $3.14 and its 200-day moving average price is $2.69. The stock has a market capitalization of $6.16 billion, a PE ratio of -15.24 and a beta of 0.03. ImmunityBio has a twelve month low of $1.83 and a twelve month high of $8.28.

Institutional Investors Weigh In On ImmunityBio

Institutional investors and hedge funds have recently modified their holdings of the company. Slow Capital Inc. acquired a new position in ImmunityBio in the 3rd quarter valued at $25,000. Truist Financial Corp purchased a new position in ImmunityBio in the third quarter valued at about $27,000. Swiss Life Asset Management Ltd purchased a new stake in shares of ImmunityBio during the 3rd quarter valued at about $27,000. Diversify Advisory Services LLC purchased a new stake in shares of ImmunityBio during the second quarter valued at approximately $27,000. Finally, Summit X LLC purchased a new stake in ImmunityBio during the 2nd quarter worth $28,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insiders Place Their Bets

In other news, Director Barry J. Simon sold 151,967 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the sale, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christobel Selecky sold 50,000 shares of ImmunityBio stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The SEC filing for this sale provides additional information. Insiders sold a total of 226,967 shares of company stock worth $1,531,912 over the last ninety days. Corporate insiders own 69.48% of the company’s stock.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.